Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dasatinib, although relatively specific for ABL, BCR-ABL and the SFKs, it possesses a broad-spectrum of inhibition of kinases including Kit, PDGFR, EphA receptors and several others (Hantschel et al., 2008).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hantschel et al., 2008
In the citing paper
“We recognize that while dasatinib primarily targets SFKs and BCR-ABL, it also inhibits other kinases including c-KIT, PDGFRβ, EPHA2, among others [41].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [41]
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“In addition to these cases of so-called secondary imatinib resistance, approximately 15% of patients with chronic phase CML do not achieve a complete cytogenetic response on imatinib at the standard dose of 400 mg [4].”
BackgroundGlobal Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317 · cited 1×
“DDR1 is emerging as an important player in immunity as well as many tumours, in particular in non-small cell lung cancer [16].”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“Here, a library of *150 to 200 selected kinases are expressed as phage particle fusion proteins and the binding affinity of kinase inhibitors is inferred by competition assays [9,10].”
BackgroundOverriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796 · cited 2×
“Of these second generation inhibitors, dasatinib (Sprycel, BMS-354825, Bristol-Myers Squibb) has been approved for the treatment of adults with CML and BCR-ABL-positive acute lymphoblastic leukemia with imatinib resistance or intolerance to previous therapy [5].”
BackgroundCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 2×
“imatinib-resistant forms with the exception of the T315I (gatekeeper) mutation [5,6].”
BackgroundThe development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879 · cited 2×
“Therefore, BCR-ABL is a suitable drug target, and research on this kinase cumulated in the discovery of imatinib (Gleevec1, STI-571), which is currently frontline therapy in CML. Imatinib is a relatively weak inhibitor of BCRABL with an IC50 in the upper nano-molar range, but has remarkable specificity, targeting only…”
BackgroundSelf-citationRix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., et al. (2007) · Blood · doi:10.1182/blood-2007-07-102061 · Cited by 671
Self-citationInhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554 · cited 2×
“Also in the case of dasatinib, kinases such as the ABL and SRC had been already confirmed and more had been postulated to be potential targets [9].”
Background
Research works printed but not linked: 1
- le Coutre P, Blood
Cited by
Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
Lennartsson, J., & Rönnstrand, L. (2012) · Physiological Reviews · doi:10.1152/physrev.00046.2011 · Cited by 825
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Role of ABL family kinases in cancer: from leukaemia to solid tumours
Greuber, E. K., Smith-Pearson, P., Wang, J., & Pendergast, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3563 · Cited by 432
Discoidin domain receptor tyrosine kinases: new players in cancer progression
Valiathan, R. R., Marco, M., Leitinger, B., Kleer, C. G., & Fridman, R. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9346-z · Cited by 383
“and thus, many of the TKIs used today in the clinic are known to target multiple kinases including DDRs [164–166].”
Metadata
- Authors
- Hantschel, O., Rix, U., & Superti-Furga, G.
- Affiliations
- Austrian Academy of Sciences (AT)
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 49
- Issue
- 4
- Pages
- 615-619
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W2034862875
- Cited by
- 256
- References
- 17
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 14 · 2022: 15 · 2021: 14 · 2020: 21 · 2019: 10 · 2018: 16 · 2017: 19 · 2016: 10 · 2015: 17 · 2014: 15 · 2013: 19 · 2012: 23
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Locations
- Leukemia & lymphoma/Leukemia and lymphoma (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BCR-ABL tyrosine kinase inhibitors, imatinib, nilotinib, dasatinib, chronic myeloid leukemia, target specificity, imatinib resistance, second-generation tyrosine kinase inhibitors
- MeSH terms
- Imatinib Mesylate, Dasatinib, Benzamides, Humans, Piperazines, Pyrimidines, Thiazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Drug Delivery Systems, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.